The Medicines Co.'s new CEO Mark Timney took over the helm in December to execute a straightforward business plan: shepherd the RNAi therapeutic inclisiran successfully through Phase III development and find a buyer for the cholesterol lowering medicine.
"There is no doubt in my mind to really fulfill its full potential, [inclisiran] is better off in the hands...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
